Abstract: An antioxidant substance which is a green leaf component in a green plant, comprising a component which is substantially insoluble in n-hexane but soluble in an aqueous ethanol solution having a water content of 0 to 80% by volume. The substance has an antioxidant activity as potent as or more potent than .alpha.-tocopherol, and is useful as an antioxidant for use in the field of foods, and medicines. Particularly, the antioxidant substance can be used for maintaining the freshness and quality of foods or storage thereof. The substance can be blended with cosmetics for skin and hair and are useful for the prevention of spots, freckles, chapping and sunburn.

Abstract: An antioxidant substance which is a green leaf component in a green plant, comprising a component which is substantially insoluble in n-hexane but soluble in an aqueous ethanol solution having a water content of 0 to 80% by volume. The substance has an antioxidant activity as potent as or more potent than .alpha.-tocopherol, and is useful as an antioxidant for use in the field of foods, and medicines. Particularly, the antioxidant substance can be used for maintaining the freshness and quality of foods or storage thereof. The substance can be blended with cosmetics for skin and hair and are useful for the prevention of spots, freckles, chapping and sunburning.

Abstract: A serum-free medium for cultivating a human monoclonal antibody-producing human/human hybridoma, said medium comprising a serum-free complete medium and at least 10.sup.-12 M but not more than 10.sup.-6 M of retinoic acid or its salt.

Abstract: A new human/human fused cell clone derived from human B cells having the ability to produce immunoglobulins and human B cells substantially lacking the ability to produce immunoglobulins, antigen-specific human immunoglobulins produced by the human/human fused cell clone, and a method of producing the human immunoglobulins. More specifically, a human/human hybridoma having the ability to produce antigen-specific human immunoglobulins, which is a human/human fused cell strain derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain; and antigen-specific human immunoglobulins produced by the human/human fused cell strain.

Abstract: Novel hybridomas, human monoclonal antibodies, and their uses are provided. Specifically CLNH5 is a human-human hybridoma which secretes IgM monoclonal antibodies specific for cervical of carcinomas. The monoclonal antibodies can find use in therapy and diagnosis, both in vitro and in vivo.The hybridoma CLNH5 was deposited at the A.T.C.C. for patent purposes as defined in M.P.E.P. 608.01(p) on Jan. 28, 1983 and given A.T.C.C. Accession No. HB8206.